We have a proven legacy in delivering meaningful therapies for difficult-to-treat diseases, and working to truly understand and respond to the therapeutic and support needs of individual patients.

Valuable solutions for patients

With deep expertise across our therapeutic areas and products, we offer valuable solutions that address the entire patient experience. We believe we have an obligation to solve challenges facing those impacted by difficult-to-treat diseases, which is why we are passionate about offering drug delivery devices for a number of our therapies, as well as comprehensive support services and patient education resources across all of our therapeutic areas of focus.

Browse the programs in our pipeline to see what we're currently working on by phase, therapeutic area and compound type.

View Our Pipeline

At, U.S. healthcare professionals can find medical resources and request medical information online.


You have accessed, but for users from your part of the world, we originally designed the following web presence

Let's go

Internet Explorer is not supported

You are using an outdated browser. If you would like to use our website, please use Chrome, Firefox, Safari or other browser

Site Exit Disclaimer

You are now leaving the website of EMD Serono, the biopharma business of Merck KGaA, Darmstadt, Germany. This link will either lead to a different website maintained by EMD Serono/its global business, or a different website/resource maintained by 3rd parties.

If you are visiting a 3rd party website, we have no control over the content and are not responsible for and make no representation as to the accuracy or any other aspect of such resource or the privacy practices of such 3rd party. Providing links to a 3rd party website does not constitute EMD Serono’s endorsement of such website or the information or products presented on such website. 

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement